{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:24:50Z","timestamp":1787772290482,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The \u201cInternational System of Reporting Serous Fluid Cytology (TIS)\u201d together with cytomorphology promotes the use of ancillary techniques to resolve difficulties in reporting serous fluid cytology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To classify serous effusion fluid samples received at our department in line with \u201cTIS\u201d, indicating the risk of malignancy (ROM), and directing appropriate usage of ancillary testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Prospective study carried out from October 2021 to September 2022. The study included all pleural, ascitic, and pericardial fluid samples, reported according to \u2018TIS\u2019. Flow cytometry and immunocytochemistry were ancillary methods utilized to assist in reporting. Cases with available history and convincing correlations didn\u2019t require further assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 1200 serous effusion samples were evaluated including 604 pleural, 591 ascitic, and 5 pericardial fluid samples. After categorization, there were 23 samples in non-diagnostic (ND, 1.9%), 575 in negative for malignancy (NFM, 47.91%), 44 in atypia of undetermined significance (AUS, 3.66%), 64 in suspicious for malignancy (SFM, 5.33%), and 494 in malignant category (MAL, 41.16%). Ancillary studies were beneficial in the recategorization of 26% (11\/44) AUS cases, 29.6% (19\/64) SFM cases, and it helped refine tumor characteristics in 35.42% (175\/494) cases categorized as malignant. Final ROM calculated for each category: ND 25%, NFM 18.6%, AUS 66.6%, SFM 88%, and MAL 100%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Serous fluid is an easily obtainable sample that can provide opportunities for ancillary testing with clinical implications. In AUS and suspicious category although, diagnostic yield is increased however, a larger number of cases are required to obtain definite results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joc.joc_114_23","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:05:56Z","timestamp":1713960356000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Role of Ancillary Techniques in Reporting Serous Fluid Cytology \u2013 \u201cRedefining Categories, Refining Diagnosis\u201d"],"prefix":"10.4103","volume":"41","author":[{"given":"Shilpa","family":"Kapoor","sequence":"first","affiliation":[{"name":"Department of Oncopathology, Gujarat Cancer and Research Institute (GCRI), Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satarupa","family":"Samanta","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Gujarat Cancer and Research Institute (GCRI), Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwalpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Oncopathology, Gujarat Cancer and Research Institute (GCRI), Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"key":"R1-20260505","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jasc.2020.05.015","article-title":"The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management","volume":"9","author":"Pinto","year":"2020","journal-title":"J Am Soc Cytopathol"},{"key":"R2-20260505","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/jmp2020007","article-title":"The International System for reporting serous fluid cytopathology: How to incorporate molecular data in cytopathology reports","volume":"2","author":"Pinto","year":"2021","journal-title":"J Mol Pathol"},{"key":"R3-20260505","doi-asserted-by":"crossref","first-page":"32.","DOI":"10.25259\/CMAS_02_03_2021","article-title":"Approach to diagnostic cytopathology of serous effusions","volume":"18","author":"Shidham","year":"2021","journal-title":"Cytojournal"},{"key":"R4-20260505","doi-asserted-by":"crossref","first-page":"4.","DOI":"10.25259\/CMAS_02_09_2021","article-title":"Metastatic carcinoma in effusions","volume":"19","author":"Shidham","year":"2022","journal-title":"Cytojournal"},{"key":"R5-20260505","first-page":"448","article-title":"Positive effusion cytology as the initial presentation of malignancy","volume":"31","author":"Monte","year":"1987","journal-title":"Acta Cytol"},{"key":"R6-20260505","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cncy.22345","article-title":"The value of a tiered cytology diagnostic reporting system in assessing the risk of malignancy in indeterminate serous effusions","volume":"129","author":"Hou","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"R7-20260505","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/dc.24653","article-title":"Root cause analysis of indeterminate diagnoses in serous fluids cytopathology","volume":"49","author":"Gokozan","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"R8-20260505","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/dc.24440","article-title":"Cytohistological correlation in serous effusions using the newly proposed international system for reporting serous fluid cytopathology: Experience of an oncological center","volume":"49","author":"Lobo","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"R9-20260505","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/dc.20133","article-title":"Malignant effusions: From diagnosis to biology","volume":"31","author":"Davidson","year":"2004","journal-title":"Diagn Cytopathol"},{"key":"R10-20260505","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","article-title":"Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors","volume":"63","author":"Chu","year":"1989","journal-title":"Cancer"},{"key":"R11-20260505","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/(SICI)1097-0339(199611)15:4<292::AID-DC8>3.0.CO;2-G","article-title":"Cytopathology of serous neoplasia of the ovary and the peritoneum: Differential diagnosis from mesothelial proliferations","volume":"15","author":"Pisharodi","year":"1996","journal-title":"Diagn Cytopathol"},{"key":"R12-20260505","doi-asserted-by":"crossref","first-page":"16.","DOI":"10.25259\/CMAS_02_11_2021","article-title":"Serous cavity metastasis: Evaluation of unknown primary","volume":"19","author":"Jhala","year":"2022","journal-title":"Cytojournal"},{"key":"R13-20260505","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1309\/AJCPU0FION3RKKFO","article-title":"Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens","volume":"2","author":"Zhao","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R14-20260505","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2303.2011.00853.x","article-title":"Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma","volume":"23","author":"Kumar","year":"2012","journal-title":"Cytopathology"},{"key":"R15-20260505","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/dc.21389","article-title":"Reliability of Her2\/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma","volume":"39","author":"Shabaik","year":"2011","journal-title":"Diagn Cytopathol"},{"key":"R16-20260505","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20260505","doi-asserted-by":"crossref","first-page":"26.","DOI":"10.4103\/1742-6413.170726","article-title":"Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology","volume":"12","author":"Hjerpe","year":"2015","journal-title":"Cytojournal"},{"key":"R18-20260505","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R19-20260505","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/dc.24541","article-title":"Role of CD68 immunohistochemistry in categorizing benign nonmesothelial cell population and refining \u201catypical\u201d category in serous fluid cytology","volume":"48","author":"Savari","year":"2020","journal-title":"Diagn Cytopathol"},{"key":"R20-20260505","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/dc.24197","article-title":"The value of cytology in diagnosis of serous effusions in malignant lymphomas: An experience of a tertiary care center","volume":"47","author":"Patel","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"R21-20260505","doi-asserted-by":"crossref","first-page":"1126.","DOI":"10.3390\/diagnostics11061126","article-title":"Cytohistological correlation in pleural effusions based on the International System for Reporting Serous Fluid Cytopathology","volume":"11","author":"Pinto","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R22-20260505","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/dc.24278","article-title":"Are we ready to develop a tiered scheme for the effusion cytology? A comprehensive review and analysis of the literature","volume":"47","author":"Farahani","year":"2019","journal-title":"Diagn Cytopathol"},{"key":"R23-20260505","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/cyt.12755","article-title":"A 2-year retrospective study on pleural effusions: A cancer centre experience","volume":"30","author":"Valerio","year":"2019","journal-title":"Cytopathology"},{"key":"R24-20260505","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/(SICI)1097-0339(199906)20:6<350::AID-DC5>3.0.CO;2-7","article-title":"Diagnostic accuracy of effusion cytology","volume":"20","author":"Motherby","year":"1999","journal-title":"Diagn Cytopathol"},{"key":"R25-20260505","doi-asserted-by":"crossref","first-page":"56.","DOI":"10.1186\/s13000-022-01241-4","article-title":"A retrospective analysis of serous effusions based on the newly proposed international system for reporting serous fluid cytopathology: a report of 3633 cases in an oncological center","volume":"17","author":"Zhu","year":"2022","journal-title":"Diagn Pathol"},{"key":"R26-20260505","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cncy.22021","article-title":"Ancillary studies in pleural, pericardial, and peritoneal effusion cytology","volume":"126","author":"Sundling","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R27-20260505","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cncy.21937","article-title":"PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens","volume":"125","author":"Heymann","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"R28-20260505","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cytology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joc.joc_114_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:36:03Z","timestamp":1787769363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joc.joc_114_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/joc.joc_114_23","relation":{},"ISSN":["0970-9371","0974-5165"],"issn-type":[{"value":"0970-9371","type":"print"},{"value":"0974-5165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"2023-07-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}